US 11,926,666 B2
Bispecific antibody constructs for CDH3 and CD3
Bertram Weiss, Berlin (DE); Anna-Lena Frisk, Berlin (DE); Ruprecht Zierz, Berlin (DE); Peter Kufer, Munich (DE); Tobias Raum, Munich (DE); Doris Rau, Munich (DE); Jonas Anlahr, Munich (DE); Ralf Lutterbüse, Munich (DE); Lisa Nahrwold, Munich (DE); Christoph Dahlhoff, Munich (DE); Claudia Blümel, Munich (DE); and Patrick Hoffmann, Munich (DE)
Assigned to AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed by AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed on May 3, 2021, as Appl. No. 17/306,051.
Application 17/306,051 is a division of application No. 15/566,444, granted, now 11,028,171, previously published as PCT/EP2016/058482, filed on Apr. 18, 2016.
Claims priority of application No. 15164154 (EP), filed on Apr. 17, 2015.
Prior Publication US 2023/0041876 A1, Feb. 9, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/3053 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 22 Claims
 
1. A method for treating or ameliorating a tumor or cancer, the method comprising administering to a subject in need thereof a bispecific single chain antibody construct comprising:
a first human binding domain which binds to human CDH3 on the surface of a target cell; and
a second binding domain which binds to human CD3 on the surface of a T cell,
wherein the first binding domain comprises a VH region and a VL region selected from the group consisting of:
a) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 169, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 170, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 171, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 172, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 173, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 174;
b) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 279, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 280, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 281, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 282, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 283, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 284;
c) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 289, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 290, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 291, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 292, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 293, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 294;
d) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 299, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 300, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 301, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 302, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 303, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 304; and
e) a VH region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 309, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 310, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 311, and a VL region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 312, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 313, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 314.